Illumina, Inc. (ETR:ILU)
79.66
-4.90 (-5.79%)
Oct 10, 2025, 5:37 PM CET
Illumina Revenue
Illumina had revenue of $1.06B USD in the quarter ending June 29, 2025, a decrease of -4.77%. This brings the company's revenue in the last twelve months to $4.28B, down -3.27% year-over-year. In the year 2024, Illumina had annual revenue of $4.37B, down -2.93%.
Revenue (ttm)
$4.28B
Revenue Growth
-3.27%
P/S Ratio
3.40
Revenue / Employee
$474.42K
Employees
9,030
Market Cap
12.42B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 4.37B | -132.00M | -2.93% |
Dec 31, 2023 | 4.50B | -80.00M | -1.75% |
Jan 1, 2023 | 4.58B | 58.00M | 1.28% |
Jan 2, 2022 | 4.53B | 1.29B | 39.73% |
Jan 3, 2021 | 3.24B | -304.00M | -8.58% |
Dec 29, 2019 | 3.54B | 210.00M | 6.30% |
Dec 30, 2018 | 3.33B | 581.00M | 21.11% |
Dec 31, 2017 | 2.75B | 354.00M | 14.76% |
Jan 1, 2017 | 2.40B | 178.00M | 8.02% |
Jan 3, 2016 | 2.22B | 358.64M | 19.27% |
Dec 28, 2014 | 1.86B | 440.18M | 30.97% |
Dec 29, 2013 | 1.42B | 272.66M | 23.74% |
Dec 30, 2012 | 1.15B | 92.98M | 8.81% |
Jan 1, 2012 | 1.06B | 152.79M | 16.93% |
Jan 2, 2011 | 902.74M | 236.42M | 35.48% |
Jan 3, 2010 | 666.32M | 93.10M | 16.24% |
Dec 28, 2008 | 573.23M | 206.43M | 56.28% |
Dec 30, 2007 | 366.80M | 182.21M | 98.71% |
Dec 31, 2006 | 184.59M | 111.09M | 151.13% |
Jan 1, 2006 | 73.50M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.40B |
Carl Zeiss Meditec AG | 2.18B |
Illumina News
- 8 days ago - ILMN Stock Set to Benefit From the Launch of New BioInsight Division - Nasdaq
- 9 days ago - ILMN: Barclays Raises Price Target, Maintains Underweight Rating | ILMN Stock News - GuruFocus
- 9 days ago - Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker - Nasdaq
- 10 days ago - Illumina (ILMN) Launches BioInsight to Enhance Biologic Data Interpretation - GuruFocus
- 10 days ago - Illumina launches new business to accelerate technology and data-driven discovery - PRNewsWire
- 15 days ago - ILMN Stock vs. IQV Stock - Forbes
- 15 days ago - TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now? - Nasdaq
- 18 days ago - Illumina (ILMN) Expands Precision Oncology Efforts with New Partnerships - GuruFocus